Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes. Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage ...
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, now in development against multiple myeloma, ...
Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Chimeric Antigen Receptor T (CAR-T) cell therapy is a new type of cancer treatment that has shown great promise in treating blood cancers, such as B cell lymphomas and leukemias, and multiple myeloma.
A Janus kinase (JAK) inhibitor helped preserve beta-cell function in people with recent-onset type 1 diabetes, the phase II BANDIT trial found. Meeting the study's primary endpoint, daily baricitinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback